Matinas BioPharma Holdings Inc (MTNB)

0.62 -0.01 (-2.27%) USD  |  NYAM  |  Nov 15, 16:00
0.62 0.00 (0.00%) After-Hours: 20:00
More

Matinas BioPharma Holdings Research and Development Expense (TTM): 13.78M for June 30, 2024

Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2013. Upgrade now.
Date Value
June 30, 2024 13.78M
March 31, 2024 13.96M
December 31, 2023 14.49M
September 30, 2023 14.69M
June 30, 2023 15.10M
March 31, 2023 15.67M
December 31, 2022 16.68M
September 30, 2022 17.05M
June 30, 2022 17.97M
March 31, 2022 16.32M
December 31, 2021 14.58M
September 30, 2021 13.87M
June 30, 2021 12.58M
March 31, 2021 13.51M
December 31, 2020 14.36M
September 30, 2020 14.25M
June 30, 2020 13.59M
March 31, 2020 13.01M
December 31, 2019 11.23M
September 30, 2019 9.507M
June 30, 2019 8.215M
March 31, 2019 6.909M
Date Value
December 31, 2018 6.788M
September 30, 2018 7.394M
June 30, 2018 8.027M
March 31, 2018 8.819M
December 31, 2017 9.010M
September 30, 2017 8.26M
June 30, 2017 7.082M
March 31, 2017 5.410M
December 31, 2016 3.948M
September 30, 2016 4.010M
June 30, 2016 4.053M
March 31, 2016 4.766M
December 31, 2015 5.292M
September 30, 2015 5.596M
June 30, 2015 5.787M
March 31, 2015 5.550M
December 31, 2014 5.176M
September 30, 2014 3.988M
June 30, 2014 3.664M
March 31, 2014 2.786M
December 31, 2013 1.762M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

11.23M
Minimum
Dec 2019
17.97M
Maximum
Jun 2022
14.56M
Average
14.36M
Median
Dec 2020

Research and Development Expense (TTM) Benchmarks

Equillium Inc 38.71M
Tenon Medical Inc 2.805M
Alphatec Holdings Inc 79.76M
Merck & Co Inc 22.98B
Madrigal Pharmaceuticals Inc 281.71M